1446194-56-4 Usage
Description
Bortezomib iMpurity H, also known as N-[(1S)-2-[(3-Methylbutyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-2-pyrazinecarboxamide, is an impurity of Bortezomib (B675700). Bortezomib is the first proteasome inhibitor to be approved by the US FDA for the treatment of multiple myeloma, a type of blood cancer. It functions as a reversible inhibitor of the 26S proteasome, a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Bortezomib iMpurity H targets the ubiquitin-proteasome pathway, which plays a crucial role in the regulation of cellular processes.
Uses
Used in Pharmaceutical Industry:
Bortezomib iMpurity H is used as a reference compound for the development and quality control of Bortezomib, a proteasome inhibitor. Its presence in the drug formulation is essential to ensure the safety, efficacy, and purity of the final product. Bortezomib iMpurity H is used for [application reason] in the development of new drugs targeting the ubiquitin-proteasome pathway, as well as for the validation of analytical methods and the assessment of drug stability.
Used in Cancer Research:
In the field of cancer research, bortezomib iMpurity H is used as a tool compound to study the role of the ubiquitin-proteasome pathway in the development and progression of multiple myeloma and other cancers. Researchers use this impurity to investigate the molecular mechanisms underlying the action of proteasome inhibitors and to identify potential therapeutic targets for the treatment of cancer.
Used in Drug Delivery Systems:
Similar to gallotannin, bortezomib iMpurity H can be employed in the development of novel drug delivery systems to enhance the bioavailability, delivery, and therapeutic outcomes of Bortezomib. Various organic and metallic nanoparticles can be used as carriers for the delivery of bortezomib iMpurity H, aiming to improve the overall effectiveness of the proteasome inhibitor in cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 1446194-56-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,6,1,9 and 4 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1446194-56:
(9*1)+(8*4)+(7*4)+(6*6)+(5*1)+(4*9)+(3*4)+(2*5)+(1*6)=174
174 % 10 = 4
So 1446194-56-4 is a valid CAS Registry Number.
1446194-56-4Relevant articles and documents
Asymmetric Synthesis of α-Aminoboronates via Rhodium-Catalyzed Enantioselective C(sp3)-H Borylation
Reyes, Ronald L.,Sato, Miyu,Iwai, Tomohiro,Sawamura, Masaya
supporting information, p. 589 - 597 (2020/01/22)
α-Aminoboronic acids, isostructural boron analogues of α-amino acids, have received much attention because of the important biomedical applications implicated for compounds containing this structure. Additionally, the inherent versatility of α-aminoboronic acids as synthetic intermediates through diverse carbon-boron bond transformations makes the efficient synthesis of these compounds highly desirable. Here, we present a Rh-monophosphite chiral catalytic system that enables a highly efficient enantioselective borylation of N-adjacent C(sp3)-H bonds for a range of substrate classes including 2-(N-alkylamino)heteroaryls and N-alkanoyl- or aroyl-based secondary or tertiary amides, some of which are pharmaceutical agents or related compounds. Various stereospecific transformations of the enantioenriched α-aminoboronates, including Suzuki-Miyaura coupling with aryl halides and the Rh-catalyzed reaction with an isocyanate derivative of α-amino acid, affording a new peptide chain elongation method, have been demonstrated. As a highlight of this work, the borylation protocol was successfully applied to the catalyst-controlled site-selective and stereoselective C(sp3)-H borylation of an unprotected dipeptidic compound, allowing remarkably streamlined synthesis of the anti-cancer drug molecule bortezomib and offering a straightforward route for the synthesis of privileged molecular architectures.
